Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Tecentriq regulatory update

January 11, 2017 6:42 PM UTC

FDA accepted and granted Priority Review to an sBLA from Roche’s Genentech unit for Tecentriq atezolizumab to treat locally advanced or metastatic urothelial carcinoma in patients who are ineligible ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article